# Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®

> **NCT00319553** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 647 (actual)

## Conditions studied

- Pertussis
- Tetanus
- Diphtheria

## Interventions

- **BIOLOGICAL:** ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed
- **BIOLOGICAL:** BOOSTRIX®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed

## Key facts

- **NCT ID:** NCT00319553
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2008-10
- **Final completion:** 2008-12
- **Target enrollment:** 647 (ACTUAL)
- **Last updated:** 2012-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00319553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00319553, "Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00319553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*